Abstract
The article touches on the key stakeholders of the biotech companiesin Taiwan. It also discusses the regulatory bodies and the government funding and taxation, strengths and opportunties and Taiwan's potential.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
